Maze Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
MAZE$35.45+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of redeemable convertible preferred stock and stockholders’ deficit
(in thousands, except share data)
| Redeemable convertible · Additional · Total | |||||||
|---|---|---|---|---|---|---|---|
| preferred stock · Common stock · paid-in · Accumulated · stockholders’ | |||||||
| Shares | Amount | Shares | Amount | capital | deficit | deficit | |
| Balance as of December 31, 2022 | 203,415,024 | $383,902 | 2,371,880 | $2 | $12,810 | $(295,271) | $(282,459) |
| Exercise of stock options | — | — | 18,153 | — | 216 | — | 216 |
| Issuance of restricted stock | — | — | 20 | — | — | — | — |
| Repurchase of unvested restricted stock and early exercised stock options | — | — | (4,841) | — | — | — | — |
| Vesting of restricted stock and early exercised stock options | — | — | — | — | 63 | — | 63 |
| Stock-based compensation expense | — | — | — | — | 8,747 | — | 8,747 |
| Net loss and comprehensive loss | — | — | — | — | — | (100,415) | (100,415) |
| Balance as of December 31, 2023 | 203,415,024 | 383,902 | 2,385,212 | 2 | 21,836 | (395,686) | (373,848) |
| Issuance of Series D redeemable convertible preferred stock, net of allocated issuance costs of $2,470 | 54,394,445 | 72,551 | — | — | — | — | — |
| Issuance of Series D-1 redeemable convertible preferred stock, net of allocated issuance costs of $1,758 | 39,395,572 | 51,634 | — | — | — | — | — |
| Deemed dividend for anti-dilution adjustments to Series B and Series C redeemable convertible preferred stock upon issuance of Series D redeemable convertible preferred stock | — | — | — | — | 14,972 | (14,972) | — |
| Exercise of stock options | — | — | 74,603 | — | 765 | — | 765 |
| Issuance of restricted stock | — | — | 14 | — | — | — | — |
| Repurchase of unvested restricted stock and early exercised stock options | — | — | (12,965) | — | — | — | — |
| Vesting of restricted stock and early exercised stock options | — | — | — | — | 23 | — | 23 |
| Stock-based compensation expense | — | — | — | — | 9,646 | — | 9,646 |
| Net income and comprehensive income | — | — | — | — | — | 52,231 | 52,231 |
| Balance as of December 31, 2024 | 297,205,041 | $508,087 | 2,446,864 | $2 | $47,242 | $(358,427) | $(311,183) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.